ERBB2 and neoplasm: A direct preclinical in vivo comparison of [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3 revealed a significantly higher uptake of both radiopharmaceuticals in HER2-positive compared to HER2-negative tumours [20].